Morgan Stanley Autolus Therapeutics PLC Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Morgan Stanley holds 553,134 shares of AUTL stock, worth $885,014. This represents 0.0% of its overall portfolio holdings.

Number of Shares

553,134

Previous 1,817,955 69.57%

Holding current value

$885,014

Previous $6.6 Million 80.32%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$2.18 - $4.8 $2.76 Million - $6.07 Million	-1,264,821 Reduced 69.57%	553,134 $1.3 Million
Q3 2024 Nov 14, 2024	SELL	$3.38 - $4.69 $3.67 Million - $5.1 Million	-1,086,888 Reduced 37.42%	1,817,955 $6.6 Million
Q2 2024 Oct 17, 2024	BUY	$3.33 - $5.68 $7.37 Million - $12.6 Million	2,214,370 Added 320.7%	2,904,843 $10.1 Million
Q2 2024 Aug 14, 2024	BUY	$3.33 - $5.68 $7.37 Million - $12.6 Million	2,214,370 Added 320.7%	2,904,843 $10.1 Million
Q1 2024 Oct 17, 2024	SELL	$5.39 - $7.29 $11.9 Million - $16.1 Million	-2,214,370 Reduced 76.23%	690,473 $4.41 Million
Q1 2024 Aug 16, 2024	BUY	$5.39 - $7.29 $3.28 Million - $4.44 Million	609,104 Added 748.57%	690,473 $4.41 Million
Q1 2024 May 15, 2024	BUY	$5.39 - $7.29 $3.28 Million - $4.44 Million	609,104 Added 748.57%	690,473 $4.41 Million
Q4 2023 Aug 16, 2024	SELL	$2.13 - $6.63 $6.01 Million - $18.7 Million	-2,823,474 Reduced 97.2%	81,369 $524,000
Q4 2023 Feb 13, 2024	SELL	$2.13 - $6.63 $150,320 - $467,898	-70,573 Reduced 46.45%	81,369 $524,000
Q3 2023 Nov 15, 2023	SELL	$2.32 - $3.36 $19,423 - $28,129	-8,372 Reduced 5.22%	151,942 $354,000
Q2 2023 Aug 14, 2023	BUY	$1.64 - $3.21 $170,423 - $333,573	103,917 Added 184.26%	160,314 $381,000
Q1 2023 May 15, 2023	SELL	$1.75 - $2.25 $68,013 - $87,446	-38,865 Reduced 40.8%	56,397 $103,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $89,282 - $167,790	51,312 Added 116.75%	95,262 $180,000
Q3 2022 Nov 14, 2022	SELL	$2.04 - $3.76 $49,843 - $91,868	-24,433 Reduced 35.73%	43,950 $94,000
Q2 2022 Oct 27, 2022	SELL	$2.04 - $4.68 $218,027 - $500,179	-106,876 Reduced 60.98%	68,383 $194,000
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.68 $218,027 - $500,179	-106,876 Reduced 60.98%	68,383 $194,000
Q1 2022 Oct 27, 2022	BUY	$3.52 - $5.46 $376,203 - $583,542	106,876 Added 156.29%	175,259 $731,000
Q1 2022 May 13, 2022	BUY	$3.52 - $5.46 $68,002 - $105,481	19,319 Added 12.39%	175,259 $731,000
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $189,235 - $259,735	-37,105 Reduced 19.22%	155,940 $809,000
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $1.03 Million - $1.42 Million	193,045 New	193,045 $1.26 Million

Others Institutions Holding AUTL

# of Institutions

111

Shares Held

130M

Call Options Held

Put Options Held

116K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $145M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account